Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1992 Oct 1;176(4):1191–1195. doi: 10.1084/jem.176.4.1191

Engineered humanized dimeric forms of IgG are more effective antibodies

PMCID: PMC2119390  PMID: 1402660

Abstract

Humanized IgG1 M195 (HuG1-M195), a complementarity determining region- grafted recombinant monoclonal antibody, is reactive with CD33, an antigen expressed on myelogenous leukemia cells. M195 is in use in trials for the therapy of acute myelogenous leukemia. Since biological activity of IgG may depend, in part, on multimeric Fab and Fc clustering, homodimeric forms of HuG1-M195 were constructed by introducing a mutation in the gamma 1 chain CH3 region gene to change a serine to a cysteine, allowing interchain disulfide bond formation at the COOH terminal of the IgG. Despite similar avidity, the homodimeric IgG showed a dramatic improvement in the ability to internalize and retain radioisotope in target leukemia cells. Moreover, homodimers were 100-fold more potent at complement-mediated leukemia cell killing and antibody-dependent cellular cytotoxicity using human effectors. Therefore, genetically engineered multimeric constructs of IgG may have advantages relative to those forms that are found naturally.

Full Text

The Full Text of this article is available as a PDF (523.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borsos T., Rapp H. J. Complement fixation on cell surfaces by 19S and 7S antibodies. Science. 1965 Oct 22;150(3695):505–506. doi: 10.1126/science.150.3695.505. [DOI] [PubMed] [Google Scholar]
  2. Chapman P. B., Yuasa H., Houghton A. N. Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. J Immunol. 1990 Aug 1;145(3):891–898. [PubMed] [Google Scholar]
  3. Circolo A., Borsos T. Lysis of hapten-labeled cells by anti-hapten IgG and complement: effect of cell surface hapten density. J Immunol. 1982 Mar;128(3):1118–1121. [PubMed] [Google Scholar]
  4. Co M. S., Avdalovic N. M., Caron P. C., Avdalovic M. V., Scheinberg D. A., Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol. 1992 Feb 15;148(4):1149–1154. [PubMed] [Google Scholar]
  5. Co M. S., Deschamps M., Whitley R. J., Queen C. Humanized antibodies for antiviral therapy. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2869–2873. doi: 10.1073/pnas.88.7.2869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Finbloom D. S. Subcellular characterization of the endocytosis of small oligomers of mouse immunoglobulin G in murine macrophages. J Immunol. 1986 Feb 1;136(3):844–851. [PubMed] [Google Scholar]
  7. Gorman S. D., Clark M. R., Routledge E. G., Cobbold S. P., Waldmann H. Reshaping a therapeutic CD4 antibody. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4181–4185. doi: 10.1073/pnas.88.10.4181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Greenspan N. S., Cooper L. J. Intermolecular cooperativity: a clue to why mice have IgG3? Immunol Today. 1992 May;13(5):164–168. doi: 10.1016/0167-5699(92)90120-V. [DOI] [PubMed] [Google Scholar]
  9. Hale G., Dyer M. J., Clark M. R., Phillips J. M., Marcus R., Riechmann L., Winter G., Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988 Dec 17;2(8625):1394–1399. doi: 10.1016/s0140-6736(88)90588-0. [DOI] [PubMed] [Google Scholar]
  10. Junghans R. P., Waldmann T. A., Landolfi N. F., Avdalovic N. M., Schneider W. P., Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990 Mar 1;50(5):1495–1502. [PubMed] [Google Scholar]
  11. Kurlander R. J., Gartrell J. E. The binding and processing of monoclonal human IgG1 by cells of a human macrophage-like cell line (U937). Blood. 1983 Sep;62(3):652–662. [PubMed] [Google Scholar]
  12. Liberti P. A., Bausch D. M., Schoenberg L. M. On the mechanism of Clq binding to antibody-I. aggregation and/or distortion of IgG vs combining site-transmitted effects. Mol Immunol. 1982 Jan;19(1):143–149. doi: 10.1016/0161-5890(82)90256-5. [DOI] [PubMed] [Google Scholar]
  13. Liu A. Y., Robinson R. R., Murray E. D., Jr, Ledbetter J. A., Hellström I., Hellström K. E. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol. 1987 Nov 15;139(10):3521–3526. [PubMed] [Google Scholar]
  14. Michaelsen T. E., Garred P., Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol. 1991 Jan;21(1):11–16. doi: 10.1002/eji.1830210103. [DOI] [PubMed] [Google Scholar]
  15. Okada M., Udaka K., Utsumi S. Co-operative interaction of subcomponents of the first component of complement with IgG: a functional defect of dimeric Facb from rabbit IgG. Mol Immunol. 1985 Dec;22(12):1399–1406. doi: 10.1016/0161-5890(85)90063-x. [DOI] [PubMed] [Google Scholar]
  16. Queen C., Schneider W. P., Selick H. E., Payne P. W., Landolfi N. F., Duncan J. F., Avdalovic N. M., Levitt M., Junghans R. P., Waldmann T. A. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1989 Dec;86(24):10029–10033. doi: 10.1073/pnas.86.24.10029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Scheinberg D. A., Lovett D., Divgi C. R., Graham M. C., Berman E., Pentlow K., Feirt N., Finn R. D., Clarkson B. D., Gee T. S. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991 Mar;9(3):478–490. doi: 10.1200/JCO.1991.9.3.478. [DOI] [PubMed] [Google Scholar]
  18. Scheinberg D. A., Tanimoto M., McKenzie S., Strife A., Old L. J., Clarkson B. D. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia. 1989 Jun;3(6):440–445. [PubMed] [Google Scholar]
  19. Segal D. M., Hurwitz E. Binding of affinity cross-linked oligomers of IgG to cells bearing Fc receptors. J Immunol. 1977 Apr;118(4):1338–1337. [PubMed] [Google Scholar]
  20. Shopes B. A genetically engineered human IgG mutant with enhanced cytolytic activity. J Immunol. 1992 May 1;148(9):2918–2922. [PubMed] [Google Scholar]
  21. Shuford W., Raff H. V., Finley J. W., Esselstyn J., Harris L. J. Effect of light chain V region duplication on IgG oligomerization and in vivo efficacy. Science. 1991 May 3;252(5006):724–727. doi: 10.1126/science.1902593. [DOI] [PubMed] [Google Scholar]
  22. Stevenson F. K., Bell A. J., Cusack R., Hamblin T. J., Slade C. J., Spellerberg M. B., Stevenson G. T. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood. 1991 Mar 1;77(5):1071–1079. [PubMed] [Google Scholar]
  23. Stevenson G. T., Pindar A., Slade C. J. A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge. Anticancer Drug Des. 1989 Mar;3(4):219–230. [PubMed] [Google Scholar]
  24. Strickland R. W., Wahl L. M., Finbloom D. S. Dimers of human immunoglobulin G1 provide an insufficient signal for their degradation by human monocytes. Clin Immunol Immunopathol. 1988 Jul;48(1):10–18. doi: 10.1016/0090-1229(88)90152-3. [DOI] [PubMed] [Google Scholar]
  25. Tanimoto M., Scheinberg D. A., Cordon-Cardo C., Huie D., Clarkson B. D., Old L. J. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989 May;3(5):339–348. [PubMed] [Google Scholar]
  26. Winter G., Milstein C. Man-made antibodies. Nature. 1991 Jan 24;349(6307):293–299. doi: 10.1038/349293a0. [DOI] [PubMed] [Google Scholar]
  27. Wong J. T., Colvin R. B. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol. 1987 Aug 15;139(4):1369–1374. [PubMed] [Google Scholar]
  28. Yasmeen D., Ellerson J. R., Dorrington K. J., Painter R. H. The structure and function of immunoglobulin domains. IV. The distribution of some effector functions among the Cgamma2 and Cgamma3 homology regions of human immunoglobulin G1. J Immunol. 1976 Feb;116(2):518–526. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES